Antengene wins Australia ethics, TGA clearance for Phase I ATG-201 autoimmune trial

PUBT · 2d ago
Antengene wins Australia ethics, TGA clearance for Phase I ATG-201 autoimmune trial
  • Antengene secured Australian ethics clearance for a Phase I trial of ATG-201 in B cell-related autoimmune diseases.
  • The study can proceed under the TGA Clinical Trial Notification pathway following completion of the CTN process.
  • UCB holds worldwide exclusive rights to develop, manufacture, and commercialize ATG-201 under a prior agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608242030PR_NEWS_USPR_____CN31998) on August 25, 2026, and is solely responsible for the information contained therein.